Medical News

RSS

Exact Sciences reports total revenues of $1.3M for second-quarter 2010

Exact Sciences Corp. today announced its financial results for the second quarter ended June 30, 2010.

28 Jul 2010

Researchers establish new criteria for liver transplantation

Researchers at the University of California, San Francisco propose that treatments used on liver cancers beyond the established Milan criteria for liver transplantation may be appropriate for all patients with hepatocellular carcinoma who are listed for transplantation. Full details appear in the August issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 Jul 2010

Dyax second-quarter total revenues increase to $15.1 million

Dyax Corp. today announced financial results for the second quarter ended June 30, 2010.

28 Jul 2010

Corning second-quarter 2010 sales up 10%

Corning Incorporated today announced its results for the second quarter 2010.

28 Jul 2010

CVS Caremark second-quarter net revenues decrease $864 million to $24.0 billion

CVS Caremark Corporation, today announced revenues, operating profit, and net income for the three and six months ended June 30, 2010.

28 Jul 2010

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.

28 Jul 2010

Morinda Holdings chosen as one of the Healthiest Companies in America

Amid the glaring spotlight on healthcare reform in the US, Interactive Health Solutions published their list of the "Healthiest Companies in America" for 2010. The list is a group of 34 companies that have significantly reduced healthcare costs through employee participation in a prevention-based health program in the workplace. Morinda Holdings, Inc. (parent company of Tahitian Noni International) was chosen from over 1,300 corporations in the United Sates ranging in size from as little as 100 to over 50,000 employees, as one of the "Healthiest Companies in America."

28 Jul 2010

ViroPharma second-quarter net sales increase 33% to $109.0 million

ViroPharma Incorporated reported today its financial results for the second quarter ended June 30, 2010.

28 Jul 2010

Viking Systems extends supply contract with Boston Scientific

Viking Systems, Inc. announced today an extension of its supply contract with Boston Scientific. Based on the continued success of Boston Scientific's SpyGlass Direct Visualization System, the companies agreed to extend the term of the supply agreement through May 2012.

28 Jul 2010

Waters second-quarter 2010 sales increase 8% to $391 million

Waters Corporation reported today second quarter 2010 sales of $391 million, an increase of 8% over sales of $363 million in the second quarter of 2009. These quarterly sales include an adverse foreign currency translation impact of approximately 1%. On a GAAP basis, earnings per diluted share for the second quarter were $0.90, compared to $0.72 for the second quarter in 2009.

28 Jul 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Allos Therapeutics, Inc. today reported its financial results and business highlights for the quarter and six months ended June 30, 2010.

28 Jul 2010

Covidien acquires Somanetics for $250 million

Covidien, a leading global provider of healthcare products, today announced that it has completed the previously announced acquisition of Somanetics Corporation for an aggregate consideration of approximately $250 million, net of cash and short-term investments acquired.

28 Jul 2010

First Edition: July 28, 2010

Today's headlines reflect developments regarding the health insurance marketplace and the implementation of the new health law.

28 Jul 2010

Sun Pharma reports first-quarter fiscal 2011 results

Sun Pharmaceutical Industries Ltd. reported numbers for the quarter ending June 30, 2010.

28 Jul 2010

Water Pik launches advertising campaign to introduce consumers to new Waterpik Water Flosser

Water Pik, Inc., a leading developer and manufacturer of innovative personal healthcare products, today announced the launch of the "Say No To String" advertising campaign to introduce consumers to the new Waterpik Water Flosser and to promote it as an easier and more effective alternative to traditional string floss.

28 Jul 2010

DaVita releases second annual corporate social responsibility report

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), today released its second annual corporate social responsibility (CSR) report, which highlights the company's philanthropic, sustainability and community-building efforts through 2009.

28 Jul 2010

3Pea International meets requirements for Current Information status on Pink Sheets

3Pea International Inc., a payment solutions company, today announced that it has met all Pink Sheet legal and accounting requirements necessary to move up from No Information to Current Information status.

28 Jul 2010

SCCT names recipients of fourth annual Young Investigator Award

The Society of Cardiovascular Computed Tomography (SCCT), the leading international professional society dedicated to research, education and clinical excellence in cardiovascular computed tomography (CT), has named Dr. Raman Dusaj and Dr. Thomas Smith the recipients of the fourth annual Young Investigator Award. The Young Investigator Award was announced at SCCT's 2010 Annual Scientific Meeting in Las Vegas.

28 Jul 2010

Pharmasset announces data from PSI-352938 single ascending dose study

Pharmasset, Inc. announced today that safety and pharmacokinetic data from the PSI-352938 single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection.

28 Jul 2010

WellPoint second-quarter net income increases to $722.4 million

WellPoint, Inc. today announced that second quarter 2010 net income was $722.4 million, or $1.71 per share, including net investment gains of $19.6 million after-tax, or $0.04 per share. Net income in the second quarter of 2009 was $693.5 million, or $1.43 per share, and included net investment losses of $38.0 million after-tax, or $0.07 per share.

28 Jul 2010